US Stocks Movement: Xeris Biopharma Surges on September 29 as XP-8121 Phase III Advances and Revenue Grows
Bitget异动解读2026/09/29 16:40Xeris Biopharma September 29 Surge Interpretation
Keywords: XP-8121 Phase III Progress, Revenue Growth
1. On September 9, the company stated at the XP-8121 project webinar that the phase III registration study is planned to commence by the end of 2026, with main results expected to be released in the second half of 2028 and approval and market launch by the U.S. Food and Drug Administration anticipated in 2030; the product's peak net revenue potential is projected at $1 billion to $3 billion.
2. On August 6, the company announced total revenue of $92.1 million for the second quarter of 2026, an increase of 29% year-over-year; net product revenue was $91 million, up 34% year-over-year, with Recorlev net revenue at $56.8 million, representing an 81% increase year-over-year. The company narrowed its full-year 2026 total revenue guidance to a range of $385 million to $390 million.
(Disclaimer: This content is generated by AI technology which collects and summarizes publicly available information. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New York gold futures rose 1% intraday to $4210.10 per ounce.
The probability of a rate hike in October has dropped to 50%. The Federal Reserve's "third in command" stated: another rate hike is needed this year, but there is no need to rush.
John Williams, President of the New York Federal Reserve, stated that if the economy performs broadly in line with expectations, it may be appropriate to raise interest rates once more later this year, but the September rate hike has allowed for more observation time, and “there is no need to act in haste.” Following Williams' remarks, the market's expectation for a Federal Reserve rate hike in October fell from around 70% to about 50%.
US Stock Market Movement: Meta soars on September 29 — Enterprise AI Platform and Small Business Muse
Sector Update: Consumer Stocks Mixed Late Afternoon
Crypto prices
More
